- Home
- LSTR vs NAMS Comparison
LSTR vs NAMS Comparison
Compare LSTR & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSTR | NAMS |
|---|---|---|
| Founded | 1988 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 3.5B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | LSTR | NAMS |
|---|---|---|
| Price | $144.27 | $29.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 8 |
| Target Price | ★ $153.17 | $46.75 |
| AVG Volume (30 Days) | 672.2K | ★ 809.4K |
| Earning Date | 04-27-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.42% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.31 | N/A |
| Revenue | ★ $4,743,760,000.00 | N/A |
| Revenue This Year | $6.63 | $25.64 |
| Revenue Next Year | $9.05 | $530.85 |
| P/E Ratio | $44.97 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $119.40 | $14.06 |
| 52 Week High | $166.11 | $42.00 |
Technical Indicators
Market Signals| Indicator | LSTR | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 40.17 | 37.53 |
| Support Level | $143.61 | $23.48 |
| Resistance Level | $145.75 | $37.43 |
| Average True Range (ATR) | 6.25 | 1.76 |
| MACD | -1.21 | -0.37 |
| Stochastic Oscillator | 5.03 | 12.31 |
Price Performance
Historical ComparisonAbout LSTR Landstar System Inc.
Landstar System is an agent based asset-light third-party logistics provider focused on domestic truck brokerage. Historically, around half of its truck transportation freight is hauled by leased owner-operators with the remainder hauled by third-party broker-carriers. To a smaller degree, it offers intermodal, global air and ocean forwarding, and warehousing services. Landstar also runs a small business that offers insurance programs to captive owner-operators. It has a long history of industry-leading execution and operating profitability.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.